Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib

Anticancer Drugs. 2015 Jan;26(1):112-6. doi: 10.1097/CAD.0000000000000150.

Abstract

Renal cell cancer has been rarely reported as a cause of gastric or esophageal metastases. They usually present with gastrointestinal bleeding and most cases have been managed surgically or endoscopically. We report the case of a 38-year-old man with a 4-year history of metastatic renal cell carcinoma admitted to the emergency room with melena and anemia. At endoscopy, three esophageal polypoid lesions (middle and distal thirds) and a 7 cm mass in the gastric fundus were identified. Biopsy revealed esophageal mucosa infiltrated by renal cell carcinoma. Radiotherapy was administered (30 Gy in 10 fractions), followed by pazopanib, with excellent tolerance and without new bleeding episodes. Computed tomography scan showed complete disappearance of the esophageal and fundic lesions at 3 months follow-up. Twenty-four months after being initiated on pazopanib, there is no radiological evidence of disease. This is the first reported case showing complete remission of gastric and esophageal metastases after treatment with radiotherapy and pazopanib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / radiotherapy*
  • Carcinoma, Renal Cell / secondary
  • Combined Modality Therapy
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / radiotherapy*
  • Esophageal Neoplasms / secondary
  • Gastric Fundus / pathology
  • Humans
  • Indazoles
  • Kidney Neoplasms / pathology*
  • Male
  • Pyrimidines / therapeutic use*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / radiotherapy*
  • Stomach Neoplasms / secondary
  • Sulfonamides / therapeutic use*

Substances

  • Antineoplastic Agents
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib